Saturday, May 21, 2022
HomeLatest Pharma-NewsHikma and Arecor announce exclusive agreement to co-develop a new, ready-to-use injectable...

Hikma and Arecor announce exclusive agreement to co-develop a new, ready-to-use injectable medicine in the US using Arestat™ technology

Jan 09, 2020: Hikma Pharmaceuticals and Arecor new joint agreement is set to co-develop new, ready-to-use injectable medicine in the US through Hikma’s affiliate, Hikma Pharmaceuticals USA.

The companies have revealed that the product is being developed using Arecor’s proprietary drug formulation technology platform Arestat and currenty used to enhance the properties of approved therapeutic proteins and peptides in order to deliver new reformulations of existing, complex products.

- Advertisement -

Hikma said that it will looking for approval for the product under the US Food and Drug Administration’s 505(b)(2) regulatory pathway, with filing expected in 2021. https://www.hikma.com/newsroom/article-i4639-hikma-and-arecor-announce-exclusive-agreement-to-develop-and-commercialise-ready-to-use-medicine-using-arestat-technology/

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular